Assessment of subclinical right ventricular dysfunction in Systemic Sclerosis (SSc) using blood oxygen level dependent (BOLD) myocardial resonance imaging and strain echocardiography

Flinders Medical Centre0 个研究点目标入组 88 人开始时间: 2021年7月16日最近更新: 2021年7月26日

适应症

试验速览

暂无简介。

•Patient population:
•-Male and female aged greater than/ equal to 18 years
•-Confirmed diagnosis of systemic sclerosis
•-Screen negative for PAH based on Australian Scleroderma Interest Group (ASIG) algorithm or normal mean PAP (8-20 mmHg; assessed by right heart catheterisation). (Screen negative implies NT-proBNP < 210 pg/ml and pulmonary function test demonstrating DLCO > 70% predicted with FVC/DLCO <1.8)
•-Normal echocardiography.
•-No history of cardiac disease (myocardial infarction, angina, cardiomyopathy/heart failure, pulmonary thromboembolism and significant valvular heart disease).
•Normal healthy controls:
•-Male and female aged greater than/ equal to 18 years
•-No history of cardiac disease
•-Normal screening echocardiogram (post consent) which includes assessment of left and right ventricular function, diastolic function and pulmonary artery pressures

•-Inability to provide informed consent
•-Prior documented LV/RV systolic dysfunction.
•-Presence of significant coronary artery disease (>50% stenosis).
•-Contraindications of CMR, including:
•o Extreme claustrophobia
•o Implantable cardiac devices and other contra-indications to CMR (metal in eyes, intracranial clips)
•o Inability to lie flat for one hour
•-Contraindication to gadolinium, including:
•o Estimated Glomerular Filtration Rate (eGFR) of <45mL/min/1.73m2
•-Contraindications to adenosine, including:
•o second or third degree atrioventricular block
•o obstructive pulmonary disease
•o dipyridamole use

发起方